Interim report
Page 1
November 2, 2026 SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr SSSSSeeeeecccccooooonnnnnddddd QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr (((((IIIIInnnnnttttteeeeerrrrriiiiimmmmm PPPPPeeeeerrrrriiiiioooooddddd))))) FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((UUUUUnnnnndddddeeeeerrrrr IIIIIFFFFFRRRRRSSSSS))))) Company name: Sumitomo Chemical Co., Ltd. Listing: Tokyo Stock Exchange Securities code: 4005 URL: https://www.sumitomo-chem.co.jp/english/ Representative: Nobuaki Mito, Representative Director & President Inquiries: Shoko Wato, General Manager, Corporate Communications Dept. Telephone: +81-3-5201-0200 Scheduled date to commence dividend payments: December 2, 2026 Scheduled date to file semi-annual securities report: November 10, 2026 Preparation of supplementary material on financial results: Yes Holding of financial results briefing: Yes (for institutional investors and analysts) (All amounts are rounded to the nearest million yen.) 11111..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr SSSSSeeeeecccccooooonnnnnddddd QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr (((((IIIIInnnnnttttteeeeerrrrriiiiimmmmm PPPPPeeeeerrrrriiiiioooooddddd))))) FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 tttttooooo SSSSSeeeeepppppttttteeeeemmmmmbbbbbeeeeerrrrr 3333300000,,,,, 22222000002222266666))))) (((((11111))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss (Percentages indicate year-on-year changes.) Sales revenue Core operating income Operating income Net income Net income attributable to owners of the parent Total comprehensive income Millions of yen % Millions of yen % Millions of yen % Millions of yen % Millions of yen % Millions of yen % Q2 FY2026 1,172,787 7.1 144,531 32.9 138,058 33.2 105,651 16.2 82,875 108.8 162,193 35.8 Q2 FY2025 1,095,394 (11.8) 108,716 268.8 103,685 (14.5) 90,929 － 39,699 － 119,446 － Basic earnings per share Diluted earnings per share Yen Yen Q2 FY2026 50.08 50.07 Q2 FY2025 24.26 24.25 Reference: Share of profit or loss of investments accounted for using the equity method Q2 FY2026: ¥ 36,695 million Q2 FY2025: ¥ (27,339) million Income before taxes Q2 FY2026: ¥ 121,927 million Q2 FY2025: ¥ 87,898 million *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn Total assets Total equity Equity attributable to owners of the parent Ratio of equity attributable to owners of the parent to total assets As of Millions of yen Millions of yen Millions of yen % September 30, 2026 3,626,081 1,482,626 1,165,298 32.1 March 31, 2026 3,405,041 1,236,673 1,008,644 29.6
Page 2
22222..... DDDDDiiiiivvvvviiiiidddddeeeeennnnndddddsssss Dividends per share 1st quarter end 2nd quarter end 3rd quarter end Year- end Annual Yen Yen Yen Yen Yen FY2025 － 6.00 － 7.50 13.50 FY2026 － 8.00 FY2026 (Forecast) － 9.00 17.00 Note: Revision of dividend forecasts from the latest announcement: Yes 33333..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaassssstttttsssss fffffooooorrrrr FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 tttttooooo MMMMMaaaaarrrrrccccchhhhh 3333311111,,,,, 22222000002222277777))))) (Percentages indicate year-on-year changes.) Sales revenue Core operating income Operating income Net income attributable to owners of the parent Basic earnings per share Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen Full FY2026 2,490,000 6.9 270,000 29.6 215,000 41.7 90,000 47.7 54.27 Note: Revision of financial forecasts from the latest announcement: Yes NNNNNooooottttteeeeesssss::::: (1) Significant changes in the scope of consolidation during the period: Yes Newly included: 1 company (Prime Polymer Co., Ltd. *) Excluded: － *Equity-method associate (2) Changes in accounting policies and changes in accounting estimates (i) Changes in accounting policies required by IFRS: Yes (ii) Changes in accounting policies due to other reasons: None (iii) Changes in accounting estimates: None (3) Number of shares issued (common shares) (i) Total number of shares issued at the end of the period (including treasury shares) As of September 30, 2026 1,662,978,884 shares As of March 31, 2026 1,657,914,399 shares (ii) Number of treasury shares at the end of the period As of September 30, 2026 506,599 shares As of March 31, 2026 6,500,914 shares (iii) Average number of shares outstanding during the period Six Months ended September 30, 2026 1,654,847,426 shares Six Months ended September 30, 2025 1,636,596,564 shares *This summary of financial results is exempt from audit procedures. *Notes to appropriate use of forecasts and other special items: Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates. *This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Page 3
1 Attachments 1. Summary of Operating Results for Second Quarter (Interim Period) Fiscal Year 2026 ....................................................................... 2 (1) Operating Results ........................................................................................................................... 2 (2) Consolidated Financial Position ...................................................................................................... 3 (3) Consolidated Forecast and Other Forward-Looking Information .................................................... 3 2. Consolidated Financial Statements and Major Notes .......................................................................... 5 (1) Consolidated Statement of Financial Position ................................................................................ 5 (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income ....................................................................... 7 (3) Consolidated Statement of Changes in Equity ............................................................................... 9 (4) Consolidated Statement of Cash Flows .........................................................................................11 (5) Notes to Consolidated Financial Statements ..................................................................................12 (Going Concern Assumption) ................................................................................................12 (Changes in Accounting Policies) ................................................................................................12 (Segment Information) ................................................................................................13
Page 4
2 11111..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr SSSSSeeeeecccccooooonnnnnddddd QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr (((((IIIIInnnnnttttteeeeerrrrriiiiimmmmm PPPPPeeeeerrrrriiiiioooooddddd))))) FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((11111))))) OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss The Group's sales revenue for Q2 FY2026 increased by ¥77.4 billion compared to Q2 FY2025, to ¥1,172.8 billion. In terms of profits and losses, core operating income* was ¥144.5 billion, operating income was ¥138.1 billion, and net income attributable to owners of the parent was ¥82.9 billion. Results in every category of income were higher than in Q2 FY2025. The Company decided to pay an interim dividend of ¥8 per share. *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. The financial results by reportable segment for Q2 FY2026 are as follows: AAAAAgggggrrrrrooooo &&&&& LLLLLiiiiifffffeeeee SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss Sales of crop protection products remained steady in Japan, but the recovery of the business environment outside of Japan has been slow. Profit margins for methionine (feed additives) improved amid temporary supply concerns stemming from the situation in the Middle East. In addition, the weaker yen also had a positive effect on sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue increased by ¥13.5 billion compared to Q2 FY2025, to ¥226.5 billion. Core operating income increased by ¥9.6 billion compared to Q2 FY2025, to ¥20.8 billion. IIIIICCCCCTTTTT &&&&& MMMMMooooobbbbbiiiiillllliiiiitttttyyyyy SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss Display-related materials were impacted by fundamental structural reforms implemented for the polarizing film business for large-size liquid crystal displays and the resulting decline in capital gains. In semiconductor processing materials, there was an increase in both sales revenue and core operating income from a growth in demand for high-purity chemicals and photoresists. In addition, the weaker yen also had a positive effect on sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue increased by ¥28.4 billion compared to Q2 FY2025, to ¥311.9 billion. Core operating income decreased by ¥1.2 billion from Q2 FY2025, to ¥31.9 billion. AAAAAdddddvvvvvaaaaannnnnccccceeeeeddddd MMMMMeeeeedddddiiiiicccccaaaaalllll SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss Sales revenue was about the same level as Q2 FY2025 at ¥21.5 billion. On the other hand, the core operating loss from a different product mix of active pharmaceutical ingredients and intermediates further deteriorated by ¥2.3 billion compared to Q2 FY2025, to a loss of ¥3.7 billion. EEEEEsssssssssseeeeennnnntttttiiiiiaaaaalllll &&&&& GGGGGrrrrreeeeeeeeeennnnn MMMMMaaaaattttteeeeerrrrriiiiiaaaaalllllsssss Although selling prices were raised in response to the increase in market prices for raw materials and products, sales revenue decreased by ¥8.3 billion compared to Q2 FY2025, to ¥320.9 billion. This was due to a decrease in shipments from the sales subsidiary after discontinuing the resale of products from Rabigh Refining and Petrochemical Company (hereinafter, "Petro Rabigh"), an affiliated company accounted for using the equity method. Core operating income improved by ¥80.7 billion compared to Q2 FY2025, to ¥62.1 billion. This reflected an improvement in Petro Rabigh's performance due to the situation in the Middle East, as well as a rise in market prices for synthetic resins and other materials, which led to a gain on the difference between the inventory valuation of these materials and their increased market price.
Page 5
3 SSSSSuuuuummmmmiiiiitttttooooommmmmooooo PPPPPhhhhhaaaaarrrrrmmmmmaaaaa There was an increase in sales revenue from a growth in sales of ORGOVYX ® (therapeutic agent for advanced prostate cancer) and GEMTESA ® (therapeutic agent for overactive bladder) in the U.S. This offset the decrease in revenue from the partial transfer of the Group’s interest in its Asian business in the previous fiscal year. As a result, sales revenue increased by ¥39.4 billion compared to Q2 FY2025, to ¥265.5 billion. Core operating income decreased by ¥53.8 billion compared to Q2 FY2025, to ¥43.6 billion. This was due to the absence of the gain from the partial transfer of the Group's interest in its Asian business in the previous fiscal year, as well as increases in selling, general and administrative expenses and R&D expenses. These expenses increased due to higher promotional spending to boost sales revenue in the U.S., the acceleration of clinical trials in the area of oncology, advancements in the area of neuropsychiatry, and other factors. Sales revenue and core operating income differ between this segment and the results reported by Sumitomo Pharma Co., Ltd., a consolidated subsidiary of Sumitomo Chemical Co., Ltd., due to the Group's contract development and manufacturing organization business for regenerative medicine and cell therapy products not being included in this segment and because of the Group's consolidated account reporting. OOOOOttttthhhhheeeeerrrrrsssss In addition to the above five segments, the Group supplies electric power and steam, and also provides transportation and warehousing. Sales revenue increased by ¥3.9 billion compared to Q2 FY2025, to ¥26.5 billion. Core operating income increased by ¥0.5 billion compared to Q2 FY2025, to ¥3.8 billion. (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn As of the end of Q2 FY2026, total assets increased by ¥221.0 billion compared to the end of FY2025, to ¥3,626.1 billion. Trade and other receivables as well as inventories increased due to higher raw material prices. Total liabilities decreased by ¥24.9 billion compared to the end of FY2025, to ¥2,143.5 billion. Interest-bearing liabilities decreased by ¥64.1 billion compared to the end of FY2025, to ¥1,087.4 billion. Total equity (including non-controlling interests) increased by ¥246.0 billion compared to the end of FY2025, to ¥ 1,482.6 billion, because of increases in non-controlling interests and capital surplus mainly due to capital increase through a public offering conducted by Sumitomo Pharma Co., Ltd. during Q1 FY2026. The ratio of equity attributable to the owners of the parent to total assets increased by 2.5 percentage points compared to the end of FY2025, to 32.1%. (((((33333))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnddddd OOOOOttttthhhhheeeeerrrrr FFFFFooooorrrrrwwwwwaaaaarrrrrddddd-----LLLLLooooooooookkkkkiiiiinnnnnggggg IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn Based on recent performance trends, the Company has made revisions to its consolidated financial forecast for the full year ending March 31, 2027, previously announced on May 14, 2026, as detailed below. RRRRReeeeevvvvviiiiisssssiiiiiooooonnnnnsssss tttttooooo CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaasssssttttt fffffooooorrrrr ttttthhhhheeeee FFFFFuuuuullllllllll YYYYYeeeeeaaaaarrrrr EEEEEnnnnndddddiiiiinnnnnggggg MMMMMaaaaarrrrrccccchhhhh 3333311111,,,,, 22222000002222277777 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 ––––– MMMMMaaaaarrrrrccccchhhhh 3333311111,,,,, 22222000002222277777))))) (Millions of yen) Sales Revenue Core Operating Income Operating Income Net Income Attributable to Owners of the Parent Earnings per Share (yen) Previous forecast (A) 2,360,000 215,000 177,000 70,000 42.40 Revised forecast (B) 2,490,000 270,000 215,000 90,000 54.27 Variance in amount (B-A) 130,000 55,000 38,000 20,000 Variance in percentage (%) 5.5% 25.6% 21.5% 28.6% Results for the full year ended March 31, 2026 2,328,515 208,376 151,744 60,947 37.16 RRRRReeeeeaaaaasssssooooonnnnnsssss fffffooooorrrrr ttttthhhhheeeee RRRRReeeeevvvvviiiiisssssiiiiiooooonnnnn Regarding the consolidated financial forecast for FY2026, shipments of semiconductor processing materials in the ICT & Mobility Solutions segment are expected to increase. In the Essential & Green Materials segment, the Company took into account uncertainty in the business environment and incorporated risks into its previous financial forecast, but the Company has made steady progress in its business activities. Additionally, GEMTESA ® sales have increased in North America within the Sumitomo Pharma segment. Therefore, the Company expects sales revenue and core operating income to exceed its previous forecast. Operating income and net income attributable to owners of the parent are also expected to exceed the previous forecast due to the increase in core operating income.
Page 6
4 (Supplemental information) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaasssssttttt bbbbbyyyyy SSSSSeeeeegggggmmmmmeeeeennnnnttttt fffffooooorrrrr ttttthhhhheeeee FFFFFuuuuullllllllll YYYYYeeeeeaaaaarrrrr EEEEEnnnnndddddiiiiinnnnnggggg MMMMMaaaaarrrrrccccchhhhh 3333311111,,,,, 22222000002222277777 (Millions of yen) FY2026 Previous Forecast (A) FY2026 Revised Forecast (B) Variance in Amount (B-A) Agro & Life Solutions Sales revenue 560,000 570,000 10,000 Core operating income 65,000 65,000 - ICT & Mobility Solutions Sales revenue 590,000 610,000 20,000 Core operating income 55,000 60,000 5,000 Advanced Medical Solutions Sales revenue 60,000 60,000 - Core operating income 3,000 3,000 - Essential & Green Materials Sales revenue 560,000 630,000 70,000 Core operating income 20,000 75,000 55,000 Sumitomo Pharma Sales revenue 540,000 565,000 25,000 Core operating income 94,000 108,000 14,000 Others & Adjustments Sales revenue 50,000 55,000 5,000 Core operating income (22,000) (41,000) (19,000) Total Sales revenue 2,360,000 2,490,000 130,000 Core operating income 215,000 270,000 55,000
Page 7
5 22222..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSStttttaaaaattttteeeeemmmmmeeeeennnnntttttsssss aaaaannnnnddddd MMMMMaaaaajjjjjooooorrrrr NNNNNooooottttteeeeesssss (((((11111))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn Millions of yen As of September 30, 2026 As of March 31, 2026 AAAAAsssssssssseeeeetttttsssss Current assets: Cash and cash equivalents ¥ 208,432 ¥ 208,589 Trade and other receivables 636,997 608,670 Other financial assets 70,616 47,551 Inventories 653,394 595,471 Other current assets 49,545 47,429 Subtotal 1,618,984 1,507,710 Assets held for sale 4,039 － Total current assets 1,623,023 1,507,710 Non-current assets: Property, plant and equipment 772,704 770,688 Goodwill 275,141 275,711 Intangible assets 215,854 225,334 Investments accounted for using the equity method 270,136 203,862 Other financial assets 362,548 301,222 Retirement benefit assets 34,833 52,222 Deferred tax assets 41,680 39,227 Other non-current assets 30,162 29,065 Total non-current assets 2,003,058 1,897,331 Total assets ¥ 3,626,081 ¥ 3,405,041
Page 8
6 Millions of yen As of September 30, 2026 As of March 31, 2026 LLLLLiiiiiaaaaabbbbbiiiiillllliiiiitttttiiiiieeeeesssss aaaaannnnnddddd eeeeeqqqqquuuuuiiiiitttttyyyyy LLLLLiiiiiaaaaabbbbbiiiiillllliiiiitttttiiiiieeeeesssss Current liabilities: Bonds and borrowings ¥ 246,785 ¥ 241,422 Trade and other payables 529,828 464,422 Other financial liabilities 48,928 63,737 Income taxes payable 18,670 7,022 Provisions 107,129 110,408 Other current liabilities 97,560 114,335 Subtotal 1,048,900 1,001,346 Liabilities directly associated with assets held for sale 824 － Total current liabilities 1,049,724 1,001,346 Non-current liabilities: Bonds and borrowings 840,581 910,033 Other financial liabilities 83,204 87,885 Retirement benefit liabilities 22,407 22,084 Provisions 23,868 26,383 Deferred tax liabilities 93,639 78,321 Other non-current liabilities 30,032 42,316 Total non-current liabilities 1,093,731 1,167,022 Total liabilities 2,143,455 2,168,368 EEEEEqqqqquuuuuiiiiitttttyyyyy Share capital 90,298 90,179 Capital surplus 40,249 1,966 Retained earnings 727,938 655,384 Treasury shares (207) (2,650) Other components of equity 307,020 263,765 Equity attributable to owners of the parent 1,165,298 1,008,644 Non-controlling interests 317,328 228,029 Total equity 1,482,626 1,236,673 Total liabilities and equity ¥ 3,626,081 ¥ 3,405,041
Page 9
7 (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee aaaaannnnnddddd CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCooooommmmmppppprrrrreeeeehhhhheeeeennnnnsssssiiiiivvvvveeeee IIIIInnnnncccccooooommmmmeeeee CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee Second Quarter (Interim Period) ended September 30, 2026 and 2025 Millions of yen Q2 FY2026 Q2 FY2025 Sales revenue ¥ 1,172,787 ¥ 1,095,394 Cost of sales (793,921) (749,314) Gross profit 378,866 346,080 Selling, general and administrative expenses (287,364) (273,398) Other operating income 19,968 66,703 Other operating expenses (10,107) (8,361) Share of profit (loss) of investments accounted for using the equity method 36,695 (27,339) Operating income 138,058 103,685 Finance income 12,976 7,105 Finance expenses (29,107) (22,892) Income before taxes 121,927 87,898 Income tax expenses (16,276) 3,031 Net income 105,651 90,929 Net income attributable to: Owners of the parent 82,875 39,699 Non-controlling interests 22,776 51,230 Net income ¥ 105,651 ¥ 90,929 Yen Q2 FY2026 Q2 FY2025 Earnings per share: Basic earnings per share 50.08 24.26 Diluted earnings per share 50.07 24.25
Page 10
8 CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCooooommmmmppppprrrrreeeeehhhhheeeeennnnnsssssiiiiivvvvveeeee IIIIInnnnncccccooooommmmmeeeee Second Quarter (Interim Period) ended September 30, 2026 and 2025 Millions of yen Q2 FY2026 Q2 FY2025 Net income ¥ 105,651 ¥ 90,929 Other comprehensive income: Items that will not be reclassified to profit or loss Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income 32,171 17,850 Remeasurements of defined benefit plans 4,619 249 Share of other comprehensive income of investments accounted for using the equity method 2,961 1,766 Total items that will not be reclassified to profit or loss 39,751 19,865 Items that may be subsequently reclassified to profit or loss Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income － 58 Cash flow hedges 281 (114) Exchange differences on conversion of foreign operations 13,201 12,564 Share of other comprehensive income of investments accounted for using the equity method 3,309 (3,856) Total items that may be subsequently reclassified to profit or loss 16,791 8,652 Other comprehensive income, net of taxes 56,542 28,517 Total comprehensive income 162,193 119,446 Total comprehensive income attributable to: Owners of the parent 134,247 67,530 Non-controlling interests 27,946 51,916 Total comprehensive income ¥ 162,193 ¥ 119,446
Page 11
9 (((((33333))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCChhhhhaaaaannnnngggggeeeeesssss iiiiinnnnn EEEEEqqqqquuuuuiiiiitttttyyyyy Second Quarter (Interim Period) ended September 30, 2026 Millions of yen Equity attributable to owners of the parent Other components of equity Share capital Capital surplus Retained earnings Treasury shares Remeasurements of financial assets measured at fair value through other comprehensive income Remeasurements of defined benefit plans Balance as of April 1, 2026 ¥ 90,179 ¥ 1,966 ¥ 655,384 ¥ (2,650) ¥ 43,393 ¥ － Net income － － 82,875 － － － Other comprehensive income － － － － 30,141 2,590 Total comprehensive income － － 82,875 － 30,141 2,590 Issuance of new shares 120 120 － － － － Purchase of treasury shares － － － (4) － － Disposal of treasury shares － 3 － 1 － － Dividends － － (12,386) － － － Changes resulting from loss of control of subsidiaries － － － － － － Changes in interest due to transactions with non-controlling interests － 38,204 － 2,446 51 － Transfer from other components of equity to retained earnings － － 2,065 － 525 (2,590) Others, net － (43) － － － － Transfer to other comprehensive income associated with assets held for sale － － － － － － Total transactions with owners 120 38,284 (10,321) 2,443 576 (2,590) Balance as of September 30, 2026 ¥ 90,298 ¥ 40,249 ¥ 727,938 ¥ (207) ¥ 74,110 ¥ － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Other comprehensive income associated with assets held for sale Equity attributable to owners of the parent Cash flow hedges Exchange differences on conversion of foreign operations Total Balance as of April 1, 2026 ¥ (214) ¥ 220,586 ¥ 263,765 ¥ － ¥1,008,644 ¥ 228,029 ¥1,236,673 Net income － － － － 82,875 22,776 105,651 Other comprehensive income 273 18,368 51,372 － 51,372 5,170 56,542 Total comprehensive income 273 18,368 51,372 － 134,247 27,946 162,193 Issuance of new shares － － － － 239 － 239 Purchase of treasury shares － － － － (4) － (4) Disposal of treasury shares － － － － 4 － 4 Dividends － － － － (12,386) (1,019) (13,405) Changes resulting from loss of control of subsidiaries － － － － － － － Changes in interest due to transactions with non-controlling interests － (6,103) (6,052) － 34,598 62,372 96,970 Transfer from other components of equity to retained earnings － － (2,065) － － － － Others, net － － － － (43) － (43) Transfer to other comprehensive income associated with assets held for sale － － － － － － － Total transactions with owners － (6,103) (8,117) － 22,408 61,353 83,761 Balance as of September 30, 2026 ¥ 59 ¥ 232,851 ¥ 307,020 ¥ － ¥1,165,298 ¥ 317,328 ¥1,482,626
Page 12
10 Second Quarter (Interim Period) ended September 30, 2025 Millions of yen Equity attributable to owners of the parent Other components of equity Share capital Capital surplus Retained earnings Treasury shares Remeasurements of financial assets measured at fair value through other comprehensive income Remeasurements of defined benefit plans Balance as of April 1, 2025 ¥ 90,059 ¥ － ¥ 640,611 ¥ (8,361) ¥ 1,186 ¥ － Net income (loss) － － 39,699 － － － Other comprehensive income － － － － 17,351 268 Total comprehensive income － － 39,699 － 17,351 268 Issuance of new shares 120 120 － － － － Purchase of treasury shares － － － (2) － － Disposal of treasury shares － (0) － 0 － － Dividends － － (9,820) － － － Changes resulting from loss of control of subsidiaries － － 1,789 － (1,611) (221) Changes in interest due to transactions with non-controlling interests － － － － － － Transfer from other components of equity to retained earnings － － (15,705) － 15,752 (47) Others, net － － － － － － Transfer to other comprehensive income associated with assets held for sale － － － － － － Total transactions with owners 120 120 (23,736) (2) 14,141 (268) Balance as of September 30, 2025 ¥ 90,179 ¥ 120 ¥ 656,574 ¥ (8,362) ¥ 32,678 ¥ － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Other comprehensive income associated with assets held for sale Equity attributable to owners of the parent Cash flow hedges Exchange differences on conversion of foreign operations Total Balance as of April 1, 2025 ¥ 87 ¥ 173,598 ¥ 174,871 ¥ 3,610 ¥ 900,790 ¥ 173,625 ¥1,074,415 Net income (loss) － － － － 39,699 51,230 90,929 Other comprehensive income (78) 15,572 33,113 (5,282) 27,831 686 28,517 Total comprehensive income (78) 15,572 33,113 (5,282) 67,530 51,916 119,446 Issuance of new shares － － － － 240 － 240 Purchase of treasury shares － － － － (2) － (2) Disposal of treasury shares － － － － 0 － 0 Dividends － － － － (9,820) (1,471) (11,291) Changes resulting from loss of control of subsidiaries － － (1,832) 43 － (3,176) (3,176) Changes in interest due to transactions with non-controlling interests － － － － － 9 9 Transfer from other components of equity to retained earnings － － 15,705 － － － － Others, net － － － － － － － Transfer to other comprehensive income associated with assets held for sale － (14,929) (14,929) 14,929 － － － Total transactions with owners － (14,929) (1,056) 14,972 (9,582) (4,638) (14,220) Balance as of September 30, 2025 ¥ 9 ¥ 174,241 ¥ 206,928 ¥ 13,300 ¥ 958,739 ¥ 220,903 ¥1,179,642
Page 13
11 (((((44444))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCaaaaassssshhhhh FFFFFlllllooooowwwwwsssss Second Quarter (Interim Period) ended September 30, 2026 and 2025 Millions of yen Q2 FY2026 Q2 FY2025 Cash flows from operating activities: Income before taxes ¥ 121,927 ¥ 87,898 Depreciation and amortization 59,143 59,974 Impairment losses 4,178 3,299 Share of (profit) loss of investments accounted for using the equity method (36,695) 27,339 Interest and dividend income (10,659) (6,138) Interest expenses 17,628 15,628 Restructuring costs 5,003 3,501 (Increase) decrease in trade receivables 22,126 27,447 (Increase) decrease in inventories (78,272) (26,282) Increase (decrease) in trade payables 80,398 (2,048) Increase (decrease) in unearned revenue (10,103) (9,380) Increase (decrease) in provisions 12 3,349 Others, net (86,050) (106,767) Subtotal 88,636 77,820 Interest and dividends received 12,443 8,902 Interest paid (16,342) (14,147) Income taxes paid (6,016) (13,422) Restructuring costs paid (12,168) (1,488) Net cash provided by (used in) operating activities 66,553 57,665 Cash flows from investing activities: Net (increase) decrease in time deposits (19,122) (4,425) Net (increase) decrease in securities (3,082) (11,279) Purchase of property, plant and equipment, and intangible assets (61,230) (61,463) Proceeds from sales of property, plant and equipment, and intangible assets 1,209 2,082 Payments for acquisition of subsidiaries (3,932) － Proceeds from sales of subsidiaries － 55,705 Purchase of other financial assets (1,815) (5,618) Proceeds from sales and redemption of other financial assets 3,749 7,339 Others, net (631) 974 Net cash provided by (used in) investing activities (84,854) (16,685) Cash flows from financing activities: Net increase (decrease) in short-term borrowings (30,313) (34,315) Net increase (decrease) in commercial paper 44,000 (37,000) Proceeds from long-term borrowings 761 6,461 Repayments of long-term borrowings (71,121) (28,232) Proceeds from issuance of bonds 39,849 － Redemption of bonds (40,000) － Repayments of lease liabilities (8,417) (8,693) Cash dividends paid (12,372) (9,841) Cash dividends paid to non-controlling interests (1,020) (1,471) Capital contribution from non-controlling interests 96,875 － Others, net (2,248) (1,683) Net cash provided by (used in) financing activities 15,994 (114,774) Effect of exchange rate changes on cash and cash equivalents 2,150 2,941 Increase (decrease) in cash and cash equivalents (157) (70,853) Cash and cash equivalents at the beginning of the year 208,589 209,838 Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale － 22,224 Cash and cash equivalents at the end of the period ¥ 208,432 ¥ 161,209
Page 14
12 (((((55555))))) NNNNNooooottttteeeeesssss tttttooooo CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSStttttaaaaattttteeeeemmmmmeeeeennnnntttttsssss GGGGGoooooiiiiinnnnnggggg CCCCCooooonnnnnccccceeeeerrrrrnnnnn AAAAAssssssssssuuuuummmmmppppptttttiiiiiooooonnnnn Not applicable. CCCCChhhhhaaaaannnnngggggeeeeesssss iiiiinnnnn AAAAAccccccccccooooouuuuunnnnntttttiiiiinnnnnggggg PPPPPooooollllliiiiiccccciiiiieeeeesssss The material accounting policies adopted for the Group's quarterly consolidated financial statements are the same as those for the consolidated financial statements for the fiscal year ended March 31, 2026, with the exception of the items described below. The items described below are the accounting standards applied by the Group starting from fiscal year ended March 31, 2027, in compliance with each transitional provision. The effect of the application of the following standards on the Group’s quarterly consolidated financial statements is immaterial. Standards Name of standards Description of new standards and amendments IFRS 7 IFRS 9 Financial Instruments: Disclosures Financial Instruments ・Clarifying the classification of financial assets (clarifying elements for assessing whether the contractual cash flows meet the solely payments of principal and interest (SPPI) criterion) ・Clarifying the date of derecognition of financial liabilities settled through electronic cash transfer systems ・Amendments to the disclosures for investments in equity instruments designated to be measured at fair value through other comprehensive income (FVTOCI) and financial instruments with contingent features that can change cash flows
Page 15
13 SSSSSeeeeegggggmmmmmeeeeennnnnttttt IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn 11111..... RRRRReeeeepppppooooorrrrrtttttaaaaabbbbbllllleeeee SSSSSeeeeegggggmmmmmeeeeennnnntttttsssss The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit. The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities. Principally in accordance with the business sectors, the Group consists of the five reportable segments based on its products and services: "Agro & Life Solutions", "ICT & Mobility Solutions", "Advanced Medical Solutions", "Essential & Green Materials", and "Sumitomo Pharma". The major products and services of each reportable segment are as follows: Reportable Segment Major Products and Services Agro & Life Solutions Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc. ICT & Mobility Solutions Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc. Advanced Medical Solutions Contract development and manufacturing organization business for advanced small-molecule drug, oligonucleotides, and regenerative medicine and cell therapy products, etc. Essential & Green Materials Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial alumina, synthetic rubber, etc. Sumitomo Pharma Small molecule pharmaceuticals 22222..... RRRRReeeeepppppooooorrrrrtttttaaaaabbbbbllllleeeee SSSSSeeeeegggggmmmmmeeeeennnnnttttt IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors. Inter-segment sales revenue is based on market prices.
Page 16
14 Second Quarter (Interim Period) Fiscal Year 2026 Millions of yen Agro & Life Solutions ICT & Mobility Solutions Advanced Medical Solutions Essential & Green Materials Sumitomo Pharma Total Others (Note 1) Adjustments (Note 2) Consoli- dated Sales revenue: Sales revenues from external customers ¥ 226,496 ¥ 311,912 ¥ 21,476 ¥ 320,862 ¥ 265,516 ¥ 1,146,262 ¥ 26,525 ¥ － ¥ 1,172,787 Inter-segment sales revenues 539 1,452 5,890 2,590 974 11,445 23,604 (35,049) － Total sales revenue 227,035 313,364 27,366 323,452 266,490 1,157,707 50,129 (35,049) 1,172,787 Segment profit (loss) : core operating income (loss) ¥ 20,802 ¥ 31,907 ¥ (3,717) ¥ 62,139 ¥ 43,560 ¥ 154,691 ¥ 3,767 ¥ (13,927) ¥ 144,531 Note 1: "Others" represents businesses such as supplying electrical power and steam, and providing transport and warehousing, which are not included in reportable segments. Note 2: ¥(13,927) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥867 million and corporate expenses of ¥(14,794) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments. Second Quarter (Interim Period) Fiscal Year 2025 Millions of yen Agro & Life Solutions ICT & Mobility Solutions Advanced Medical Solutions Essential & Green Materials Sumitomo Pharma Total Others (Note 2) Adjustments (Note 3) Consoli- dated Sales revenue: Sales revenues from external customers ¥ 212,971 ¥ 283,482 ¥ 21,142 ¥ 329,144 ¥ 226,071 ¥ 1,072,810 ¥ 22,584 ¥ － ¥ 1,095,394 Inter-segment sales revenues 504 1,453 6,391 2,432 1,051 11,831 24,772 (36,603) － Total sales revenue 213,475 284,935 27,533 331,576 227,122 1,084,641 47,356 (36,603) 1,095,394 Segment profit (loss) : core operating income (loss) ¥ 11,227 ¥ 33,109 ¥ (1,380) ¥ (18,610) ¥ 97,320 ¥ 121,666 ¥ 3,235 ¥ (16,185) ¥ 108,716 Note 1: ¥97,320 million for segment profit (core operating income) in "Sumitomo Pharma" included ¥49,544 million for gain related to business transfer. Note 2: "Others" represented businesses such as supplying electrical power and steam, and providing transport and warehousing, which were not included in reportable segments. Note 3: ¥(16,185) million for segment profit (loss) in "Adjustments" included inter-segment elimination of ¥486 million and corporate expenses of ¥(16,671) million unallocated to each reportable segment. Corporate expenses were mainly research and development expenses for company-wide research, which were not treated as attributable to specific reportable segments.
Page 17
15 Adjustments to income before taxes from core operating income were as follows: Millions of yen Q2 FY2026 Q2 FY2025 Core operating income ¥ 144,531 ¥ 108,716 Restructuring costs (5,003) (3,501) Impairment losses (4,178) (3,299) Others, net 2,708 1,769 Operating income 138,058 103,685 Finance income 12,976 7,105 Finance expenses (29,107) (22,892) Income before taxes ¥ 121,927 ¥ 87,898
Page 18
KKKKKeeeeeyyyyy FFFFFiiiiiggggguuuuurrrrreeeeesssss ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr 22222nnnnnddddd QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr (((((IIIIInnnnnttttteeeeerrrrriiiiimmmmm PPPPPeeeeerrrrriiiiioooooddddd))))) FFFFFYYYYY22222000002222266666 NNNNNooooovvvvveeeeemmmmmbbbbbeeeeerrrrr 22222,,,,, 22222000002222266666 SSSSSuuuuummmmmiiiiitttttooooommmmmooooo CCCCChhhhheeeeemmmmmiiiiicccccaaaaalllll CCCCCooooo.....,,,,, LLLLLtttttddddd..... 11111..... FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ22222 FFFFFYYYYY22222000002222266666 QQQQQ22222 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222266666 (((((RRRRReeeeevvvvviiiiissssseeeeeddddd FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnnnnnnooooouuuuunnnnnccccceeeeeddddd iiiiinnnnn NNNNNooooovvvvv.....))))) FFFFFYYYYY22222000002222255555 Sales revenue 11111,,,,,111117777722222.....88888 1,095.4 77.4 2,490.0 2,328.5 Core operating income 111114444444444.....55555 108.7 35.8 270.0 208.4 Operating income 111113333388888.....11111 103.7 34.4 215.0 151.7 Net income attributable to owners of the parent 8888822222.....99999 39.7 43.2 90.0 60.9 Basic earnings per share ¥¥¥¥¥ 5555500000.....0000088888 ¥ 24.26 ¥ 25.82 ¥ 54.27 ¥ 37.16 Return on equity 77777.....66666%%%%% 4.3% 3.3% 8.6% 6.4% Exchange rate (yen/$) 111115555599999.....4444499999 146.02 － 157.00 (2nd Half 155.00) 150.67 Naphtha price (yen/kl) 111110000077777,,,,,555550000000000 64,800 － 99,000 (2nd Half 90,000) 65,200 *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. 22222..... SSSSSaaaaallllleeeeesssss RRRRReeeeevvvvveeeeennnnnuuuuueeeee ///// CCCCCooooorrrrreeeee OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg IIIIInnnnncccccooooommmmmeeeee bbbbbyyyyy RRRRReeeeepppppooooorrrrrtttttaaaaabbbbbllllleeeee SSSSSeeeeegggggmmmmmeeeeennnnnttttt (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ22222 FFFFFYYYYY22222000002222266666 QQQQQ22222 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222266666 (((((RRRRReeeeevvvvviiiiissssseeeeeddddd FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnnnnnnooooouuuuunnnnnccccceeeeeddddd iiiiinnnnn NNNNNooooovvvvv.....))))) FFFFFYYYYY22222000002222255555 Agro & Life Solutions Sales revenue 222222222266666.....55555 213.0 13.5 570.0 519.3 Core operating income 2222200000.....88888 11.2 9.6 65.0 56.3 ICT & Mobility Solutions Sales revenue 333331111111111.....99999 283.5 28.4 610.0 574.2 Core operating income 3333311111.....99999 33.1 (1.2) 60.0 53.0 Advanced Medical Solutions Sales revenue 2222211111.....55555 21.1 0.3 60.0 58.6 Core operating income (((((33333.....77777))))) (1.4) (2.3) 3.0 2.8 Essential & Green Materials Sales revenue 333332222200000.....99999 329.1 (8.3) 630.0 678.8 Core operating income 6666622222.....11111 (18.6) 80.7 75.0 14.4 Sumitomo Pharma Sales revenue 222226666655555.....55555 226.1 39.4 565.0 451.9 Core operating income 4444433333.....66666 97.3 (53.8) 108.0 108.4 Others Sales revenue 2222266666.....55555 22.6 3.9 55.0 45.8 Core operating income 33333.....88888 3.2 0.5 4.0 4.4 Adjustments Sales revenue －－－－－ － － － － Core operating income (((((1111133333.....99999))))) (16.2) 2.3 (45.0) (31.1) Total Sales revenue 11111,,,,,111117777722222.....88888 1,095.4 77.4 2,490.0 2,328.5 Core operating income 111114444444444.....55555 108.7 35.8 270.0 208.4
Page 19
33333..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ22222 FFFFFYYYYY22222000002222266666 QQQQQ22222 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee RRRRRaaaaatttttiiiiiooooo Sales revenue 11111,,,,,111117777722222.....88888 1,095.4 77.4 7.1% Core operating income 111114444444444.....55555 108.7 35.8 32.9% of which equity-method investments 3333366666.....77777 (27.3) 64.0 － Total non-recurring items (breakdown below) (((((66666.....55555))))) (5.0) (1.4) － Restructuring costs (((((55555.....00000))))) (3.5) (1.5) － Impairment losses (((((44444.....22222))))) (3.3) (0.9) － Others 22222.....77777 1.8 0.9 － Operating income 111113333388888.....11111 103.7 34.4 33.2% Finance income/expenses (breakdown below) (((((1111166666.....11111))))) (15.8) (0.3) － (Loss) on foreign currency transactions including gain (loss) on derivatives (((((99999.....44444))))) (6.4) (3.0) － Others (((((66666.....77777))))) (9.4) 2.7 － Income before taxes 111112222211111.....99999 87.9 34.0 38.7% Income tax expenses (((((1111166666.....33333))))) 3.0 (19.3) － Net income 111110000055555.....77777 90.9 14.7 16.2% Net (income) attributable to non-controlling interests (((((2222222222.....88888))))) (51.2) 28.5 － Net income attributable to owners of the parent 8888822222.....99999 39.7 43.2 108.8% ROE 77777.....66666%%%%% 4.3% Exchange rate (yen/$) 111115555599999.....4444499999 146.02 Naphtha price (yen/kl) 111110000077777,,,,,555550000000000 64,800 Overseas sales revenue ratio 6666688888.....22222%%%%% 70.0% 44444..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) 3333300000-----SSSSSeeeeeppppp-----2222266666 3333311111-----MMMMMaaaaarrrrr-----2222266666 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee 3333300000-----SSSSSeeeeeppppp-----2222266666 3333311111-----MMMMMaaaaarrrrr-----2222266666 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee Current assets 11111,,,,,666662222233333.....00000 1,507.7 115.3 Liabilities 22222,,,,,111114444433333.....55555 2,168.4 (24.9) Cash and cash equivalents 222220000088888.....44444 208.6 (0.2) Trade and other payables 555552222299999.....88888 464.4 65.4 Trade and other receivables 666663333377777.....00000 608.7 28.3 Interest-bearing liabilities 11111,,,,,000008888877777.....44444 1,151.5 (64.1) Inventories 666665555533333.....44444 595.5 57.9 Others 555552222266666.....33333 552.5 (26.2) Others 111112222244444.....22222 95.0 29.2 Equity 11111,,,,,444448888822222.....66666 1,236.7 246.0 Non-current assets 22222,,,,,000000000033333.....11111 1,897.3 105.7 Shareholders' equity 888885555588888.....33333 744.9 113.4 Property, plant and equipment 777777777722222.....77777 770.7 2.0 Other components of equity 333330000077777.....00000 263.8 43.3 Goodwill and intangible assets 444449999911111.....00000 501.0 (10.1) Non-controlling interests 333331111177777.....33333 228.0 89.3 Others 777773333399999.....44444 625.6 113.8 Total 33333,,,,,666662222266666.....11111 3,405.0 221.0 Total 33333,,,,,666662222266666.....11111 3,405.0 221.0 Ratio of equity attributable to owners of the parent to total assets 3333322222.....11111%%%%% 29.6% 2.5% D/E ratio (times) 00000.....7777733333 0.93 (0.20)
Page 20
55555..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCaaaaassssshhhhh FFFFFlllllooooowwwwwsssss (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ22222 FFFFFYYYYY22222000002222266666 QQQQQ22222 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222255555 Cash flows from operating activities 6666666666.....66666 57.7 8.9 234.8 Cash flows from investing activities (((((8888844444.....99999))))) (16.7) (68.2) (74.8) Free cash flows (((((1111188888.....33333))))) 41.0 (59.3) 159.9 Cash flows from financing activities 1111166666.....00000 (114.8) 130.8 (199.1) Others 22222.....22222 2.9 (0.8) 15.7 Increase (decrease) in cash and cash equivalents (((((00000.....22222))))) (70.9) 70.7 (23.5) Cash and cash equivalents at the end of the period 222220000088888.....44444 161.2 47.2 208.6